NCT05969496 2026-04-13
NEOPAX
University of Colorado, Denver
Phase 2 Recruiting
Clinical Trials
64 trialsNCT05327686 2026-04-08
SAMURAI
NRG Oncology
Phase 2 Recruiting
NCT05808608 2026-04-07
A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma
West China Hospital
Phase 1/2 Active not recruiting
NCT07500831 2026-03-30
Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma
Qilu Hospital of Shandong University
Phase NA Not yet recruiting
NCT07123090 2026-03-25
SPARCC
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05738694 2026-03-17
Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
Sun Yat-sen University
Phase 3 Recruiting
NCT07469683 2026-03-13
An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Yonsei University
Phase 2 Recruiting
NCT06860386 2026-03-06
Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Suspended
NCT05805501 2026-02-12
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT07383441 2026-02-03
Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
SWOG Cancer Research Network
Phase 3 Not yet recruiting
NCT02853331 2026-02-02
KEYNOTE-426
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03092856 2025-12-17
Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
University of Southern California
Phase 2 Active not recruiting
NCT07277972 2025-12-11
Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT05363631 2025-12-10
Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab
University of Iowa
Phase 1/2 Active not recruiting
NCT03595124 2025-12-03
A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05287464 2025-11-26
International Multicentric Study ARON-1
Hospital of Macerata
Recruiting
NCT04370509 2025-11-19
Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery
University of California, San Francisco
Phase 2 Terminated
NCT03172754 2025-10-29
Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma
Fox Chase Cancer Center
Phase 1/2 Active not recruiting
NCT03438708 2025-10-02
PADRES
University of California, San Diego
Phase 2 Active not recruiting
NCT07172386 2025-09-16
Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC
Tianjin Medical University Second Hospital
Phase 2 Recruiting
NCT04458259 2025-08-28
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Pfizer
Phase 1 Terminated
NCT02684006 2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3 Completed
NCT04522323 2025-07-25
A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma
MedImmune LLC
Phase 1 Active not recruiting
NCT04337970 2025-05-28
Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT05650164 2025-03-28
J-DART2
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Completed
NCT05256472 2025-03-06
A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma
Akeso
Phase 2 Active not recruiting
NCT06364631 2025-01-16
CARE1
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Recruiting
NCT04682587 2025-01-03
To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma
Pfizer
Completed
NCT06211114 2024-11-26
Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma
Peking University Cancer Hospital & Institute
Phase 2 Recruiting
NCT01693822 2024-11-21
A-PREDICT
Institute of Cancer Research, United Kingdom
Phase 2 Completed
NCT02639182 2024-11-18
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Astellas Pharma Inc
Phase 2 Completed
NCT06690697 2024-11-15
Combination of Toripalimab and JS004 Therapy for ccRCC
Fudan University
Phase 2 Recruiting
NCT02667886 2024-10-03
Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma
X4 Pharmaceuticals
Phase 1/2 Completed
NCT04540705 2024-02-28
PIVOT IO 011
Bristol-Myers Squibb
Phase 1 Completed
NCT05012865 2023-12-06
Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART)
Pfizer
Completed
NCT04555603 2023-11-21
Axitinib Therapy Management Study
Pfizer
Withdrawn
NCT02579811 2023-06-29
Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT05817903 2023-05-08
AxIn
Consorzio Oncotech
Phase 2 Recruiting
NCT05816642 2023-04-18
Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma
RenJi Hospital
Phase NA Unknown
NCT02489695 2022-09-06
AXIPAP
Centre Leon Berard
Phase 2 Completed
NCT05263609 2022-08-02
Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib
University of Oklahoma
Phase 2 Withdrawn
NCT02493751 2022-02-18
JAVELIN Renal 100
Pfizer
Phase 1 Completed
NCT01649180 2021-08-12
PrE0801
PrECOG, LLC.
Phase 2 Terminated
NCT04995016 2021-08-06
PANDORA
Tianjin Medical University Second Hospital
Phase 2 Unknown
NCT02133742 2021-07-28
A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer
Pfizer
Phase 1 Completed
NCT04958473 2021-07-12
SAARCC
Tianjin Medical University Second Hospital
Phase 2 Unknown
NCT03494816 2021-06-30
NAXIVA
Scottish Clinical Trials Research Unit
Phase 2 Completed
NCT04637204 2021-02-01
Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in England
Ipsen
Completed
NCT01798446 2020-12-08
A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus
Seoul National University Hospital
Phase 2 Completed
NCT01806064 2020-10-19
Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma
Tracon Pharmaceuticals Inc.
Phase 1/2 Terminated